

Thomas Gruenberger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3674536/thomas-gruenberger-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143
papers

11,476
citations

44
h-index

106
g-index

151
ext. papers

13,382
ext. citations

4.8
avg, IF

5.56
L-index

#	Paper	IF	Citations
143	Effect of Goal-Directed Crystalloid versus Colloid Administration on Perioperative Hemostasis in Partial Hepatectomy: A Randomized, Controlled Trial. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
142	Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery. <i>Hepatology</i> , 2021 , 73, 1956-1966	11.2	5
141	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. <i>British Journal of Cancer</i> , 2020 , 122, 1518-1524	8.7	17
140	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020 , 46, 955-966	3.6	7
139	The Immune Phenotype of Isolated Lymphoid Structures in Non-Tumorous Colon Mucosa Encrypts the Information on Pathobiology of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
138	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020 , JCO2001225	2.2	52
137	Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 1870-1875	3.6	2
136	The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection. <i>Hepatobiliary Surgery and Nutrition</i> , 2019 , 8, 111-124	2.1	7
135	Predicting Postoperative Liver Dysfunction Based on Blood-Derived MicroRNA Signatures. <i>Hepatology</i> , 2019 , 69, 2636-2651	11.2	21
134	The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019 , 26, 791-799	3.1	12
133	EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3558-3558	2.2	1
132	Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. <i>Hepatology</i> , 2018 , 67, 1516-1530	11.2	30
131	Cure in metastatic disease: how to manage and who is the right patient in colorectal cancer?. <i>Memo - Magazine of European Medical Oncology</i> , 2018 , 11, 317-321	0.3	
130	Elevated ADAMTS13 Activity is Associated with Poor Postoperative Outcome in Patients Undergoing Liver Resection. <i>Scientific Reports</i> , 2018 , 8, 16823	4.9	3
129	Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis. <i>Annals of Surgery</i> , 2018 , 268, 894-902	7.8	43
128	Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. <i>European Journal of Cancer</i> , 2017 , 78, 7-15	7.5	30
127	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017 , 66, 305-317	7.5	17

126	Long-term outcomes of patients with 10 or more colorectal liver metastases. <i>British Journal of Cancer</i> , 2017 , 117, 604-611	8.7	35
125	Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. <i>Journal of Hepatology</i> , 2017 , 67, 1243-1252	13.4	31
124	Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity. <i>PLoS ONE</i> , 2017 , 12, e0175359	3.7	11
123	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. <i>Oncotarget</i> , 2017 , 8, 46234-46248	3.3	32
122	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2814-2821	6.1	6
121	PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 1866-1872	3.6	25
120	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, v28-v37	10.3	318
119	The profile of platelet β granule released molecules affects postoperative liver regeneration. <i>Hepatology</i> , 2016 , 63, 1675-88	11.2	54
118	Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response. <i>Oncolmmunology</i> , 2016 , 5, e1160185	7.2	9
117	The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. <i>Oncotarget</i> , 2016 , 7, 57197-57212	3.3	29
116	Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection. <i>PLoS ONE</i> , 2016 , 11, e0165481	3.7	30
115	Treatment sequence of synchronously (liver) metastasized colon cancer. <i>Digestive and Liver Disease</i> , 2016 , 48, 1119-23	3.3	12
114	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
113	Liver surgery for metastatic colorectal cancer: the surgical oncologist perspective. <i>Colorectal Cancer</i> , 2016 , 5, 115-125	0.8	0
112	Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 868-74	3.6	17
111	Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 683-9	3.6	18
110	CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1315-23	3.1	10
109	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. <i>Annals of Oncology</i> , 2015 , 26, 1728-33	10.3	6

108	Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction. <i>British Journal of Surgery</i> , 2015 , 102, 826-36	5.3	18
107	Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. <i>European Journal of Cancer</i> , 2015 , 51, 2708-17	7.5	54
106	The role of platelets and portal venous pressure fluctuations in postoperative liver regeneration. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2015 , 47, 312-318	0.9	0
105	Reply: To PMID 24277679. <i>Hepatology</i> , 2015 , 62, 319-20	11.2	
104	Reply: To PMID 24277679. <i>Hepatology</i> , 2015 , 62, 984	11.2	3
103	Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction. <i>PLoS ONE</i> , 2015 , 10, e0116985	3.7	9
102	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. <i>Pharmacogenomics Journal</i> , 2015 , 15, 521-9	3.5	8
101	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015 , 121, 1898-905	6.4	9
100	Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015 , 137, 385-394	7.5	34
99	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. <i>Annals of Oncology</i> , 2015 , 26, 702-708	10.3	190
98	Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. <i>Hepatology</i> , 2014 , 60, 257-66	11.2	80
97	Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. <i>European Journal of Cancer</i> , 2014 , 50, 912-9	7.5	140
96	Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). <i>Annals of Oncology</i> , 2014 , 25, 1018-25	10.3	166
95	B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. <i>PLoS ONE</i> , 2014 , 9, e99008	3.7	60
94	Clinical management of patients with complicated multifocal disease. <i>Cancer Imaging</i> , 2014 , 14,	5.6	78
93	Monocytes with angiogenic potential are selectively induced by liver resection and accumulate near the site of liver regeneration. <i>BMC Immunology</i> , 2014 , 15, 50	3.7	17
92	Association outcome with genes involved in immune response and checkpoints in patients with resected colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3563-3563	2.2	
91	Association of outcome with genes involved in tumor dormancy in patients with resected colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14512-e14512	2.2	

90	Influence of genetic variations of the angiopoietin and pericyte pathways in resected colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3564-3564	2.2	
89	Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. <i>European Radiology</i> , 2013 , 23, 2187-96	8	78
88	Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. <i>Cancer</i> , 2013 , 119, 2778-88	6.4	36
87	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2013 , 14, 1208-15	21.7	733
86	Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration. <i>Journal of Hepatology</i> , 2013 , 58, 1053-4	13.4	12
85	Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. <i>Radiology</i> , 2013 , 269, 777-86	20.5	60
84	Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. <i>Hpb</i> , 2013 , 15, 71-7	3.8	22
83	Cetuximab and chemotherapy in the treatment of patients with initially nonresectable colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3538-3538	2.2	3
82	Interim follow up results from a phase II study of neoadjuvant chemoembolization of resectable colorectal liver metastases (CRLM) with transcatheter hepatic therapy with irinotecan-eluting beads.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 519-519	2.2	3
81	Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. <i>Surgical Oncology</i> , 2012 , 21, 309-15	2.5	39
80	KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. <i>British Journal of Surgery</i> , 2012 , 99, 1575-82	5.3	59
79	Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. <i>Annals of Surgical Oncology</i> , 2012 , 19, 2786-96	3.1	59
78	Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0 T before hepatic surgery: reliable enough for making clinical decisions?. <i>European Journal of Radiology</i> , 2012 , 81, 2990-5	4.7	12
77	Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. <i>European Journal of Surgical Oncology</i> , 2012 , 38, 670-6	3.6	60
76	Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. <i>PLoS ONE</i> , 2012 , 7, e44450	3.7	30
75	Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection. <i>Annals of Surgical Oncology</i> , 2012 , 19, 435-42	3.1	32
74	Austrian Joint ÖGH-ÖIR-ÖHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2012 , 124, 104-10	2.3	12
73	Laparoscopic hepatectomy: an alternative to open surgery for colorectal liver metastases?. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2012 , 44, 164-167	0.9	

72	The role of biological agents in the resection of colorectal liver metastases. <i>Clinical Oncology</i> , 2012 , 24, 432-42	2.8	8
71	Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. <i>British Journal of Cancer</i> , 2012 , 107, 961-6	8.7	19
70	Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). <i>Annals of Surgery</i> , 2012 , 255, 534-9	7.8	76
69	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3508-3508	2.2	20
68	Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug eluting beads trans-arterial chemoembolization (DEBIRI-TACE): A multi-institute phase II study in resectable metastases.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3613-3613	2.2	3
67	Association of marked thrombocytopenia at postoperative day 1 with incidence of liver dysfunction, morbidity, and mortality in metastatic colorectal cancer patients undergoing liver resection.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14095-e14095	2.2	
66	Activity of neoadjuvant bevacizumab at the time of surgery after 6 weeks of preoperative cessation: A translational study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14099-e14099	2.2	
65	Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?. <i>European Journal of Radiology</i> , 2011 , 79, e1-6	4.7	67
64	Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. <i>Annals of Surgical Oncology</i> , 2011 , 18, 1644-50	3.1	42
63	Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. <i>Annals of Surgical Oncology</i> , 2011 , 18, 421-30	3.1	100
62	Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. <i>Annals of Surgical Oncology</i> , 2011 , 18, 1380-8	3.1	115
61	Surgery for liver metastases originating from sarcoma-case series. <i>Langenbeck's Archives of Surgery</i> , 2011 , 396, 1083-91	3.4	7
60	Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2011 , 98, 1752-8	5.3	36
59	Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2059-65	3.1	93
58	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2010 , 11, 38-47	21.7	73 ⁸
57	Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. <i>Lancet Oncology, The</i> , 2010 , 11, 1142-8	21.7	192
56	Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. <i>Annals of Surgery</i> , 2010 , 252, 124-30	7.8	41
55	Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. <i>CardioVascular and Interventional Radiology</i> , 2010 , 33, 41-52	2.7	107 ⁶

54	Systemic effects of anti-VEGF therapy [Mini-review. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2010 , 42, 12-16	0.9	1
53	VEGF and EGFR inhibition: opening a new door to cancer treatment. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2010 , 42, 24-28	0.9	1
52	Colorectal Cancer Liver Metastases (CLM) [ASCO 2010. <i>Memo - Magazine of European Medical Oncology</i> , 2010 , 3, 178-179	0.3	
51	Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1809-19	15.4	44
50	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. <i>Annals of Oncology</i> , 2009 , 20 Suppl 7, vii1-vii6	10.3	84
49	Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. <i>Annals of Oncology</i> , 2009 , 20, 985-92	10.3	268
48	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1547-56	6.1	25
47	Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. <i>Journal of Surgical Oncology</i> , 2009 , 100, 364-71	2.8	19
46	Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. <i>British Journal of Surgery</i> , 2009 , 96, 919-25	5.3	60
45	The EGF 61A/G polymorphism - a predictive marker for recurrence of liver metastases from colorectal cancer. <i>Wiener Klinische Wochenschrift</i> , 2009 , 121, 638-43	2.3	9
44	Criteria for resectability of colorectal cancer liver metastases [An Austrian survey and current recommendations. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2009 , 41, 213-220	0.9	
43	Austrian Consensus on the surgical treatment of colorectal liver metastases. <i>Memo - Magazine of European Medical Oncology</i> , 2009 , 2, 38-40	0.3	2
42	Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial. <i>BMC Anesthesiology</i> , 2009 , 9, 1	2.4	35
41	Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. <i>European Journal of Surgical Oncology</i> , 2009 , 35, 515-20	3.6	126
40	Colorectal Cancer Liver Metastases: Neoadjuvant Therapy with Bevacizumab 2009 , 439-444		
39	Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. <i>BMC Cancer</i> , 2008 , 8, 120	4.8	94
38	Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases. <i>Surgery</i> , 2008 , 143, 648-57	3.6	31
37	HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2008 , 49, 955-64	13.4	21

36	Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. <i>European Journal of Surgical Oncology</i> , 2008 , 34, 1231-6	3.6	68
35	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <i>Lancet, The</i> , 2008 , 371, 1007-16	4.0	1468
34	Surgery vs surgery and chemotherapy for colorectal liver metastases [Authors' reply]. <i>Lancet, The</i> , 2008 , 372, 203	4.0	
33	Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1830-5	2.2	344
32	Urgent need for a new staging system in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4828-33	2.2	122
31	Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. <i>Clinical Cancer Research</i> , 2008 , 14, 2065-74	12.9	27
30	Using bevacizumab and cetuximab before liver surgery. <i>Current Colorectal Cancer Reports</i> , 2008 , 4, 126-129		1
29	Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2008 , 15, 2787-94	3.1	119
28	Post-treatment imaging of liver tumours. <i>Cancer Imaging</i> , 2007 , 7 Spec No A, S28-36	5.6	39
27	Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. <i>British Journal of Surgery</i> , 2007 , 94, 1133-8	5.3	86
26	Authors' reply: Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases (Br J Surg 2007; 94: 1133-1138). <i>British Journal of Surgery</i> , 2007 , 95, 129-129	5.3	
25	Effects of continuous remifentanyl administration on intra-operative subcutaneous tissue oxygen tension. <i>Anaesthesia</i> , 2007 , 62, 1101-9	6.6	7
24	Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 4795-9	12.9	75
23	Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. <i>European Journal of Cancer</i> , 2007 , 43, 2037-45	7.5	203
22	Selective resection of colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 174-82	3.6	30
21	HER 2/neu protein expression in colorectal cancer. <i>BMC Cancer</i> , 2006 , 6, 123	4.8	83
20	Neoadjuvant therapy with bevacizumab. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2592-3; author reply 2593-4	3.4	30
19	Treatment and outcome of intrahepatic cholangiocellular carcinoma. <i>American Journal of Surgery</i> , 2005 , 189, 173-7	2.7	57

18	Side effects during chemotherapy predict tumour response in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2005 , 93, 744-8	8.7	31
17	Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. <i>Annals of Oncology</i> , 2004 , 15, 478-83	10.3	111
16	Resection of hilar cholangiocarcinomas: pivotal prognostic factors and impact of tumor sclerosis. <i>World Journal of Surgery</i> , 2003 , 27, 680-4	3.3	20
15	Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy. <i>Cancer</i> , 2002 , 94, 1753-9	6.4	10
14	Staged treatment of bilobar hepatic metastases from colorectal cancer. <i>The European Journal of Surgery</i> , 2002 , 168, 516-8		1
13	Long-term follow-up of surgically treated gallbladder cancer patients. <i>European Journal of Surgical Oncology</i> , 2002 , 28, 857-63	3.6	40
12	Use of absorbable mesh in the treatment of parenchymal liver injuries during orthotopic liver transplantation. <i>The European Journal of Surgery</i> , 2001 , 167, 29-34		1
11	Reduction in recurrence risk for involved or inadequate margins with edge cryotherapy after liver resection for colorectal metastases. <i>Archives of Surgery</i> , 2001 , 136, 1154-7		40
10	Echogenicity of liver metastases is an independent prognostic factor after potentially curative treatment. <i>Archives of Surgery</i> , 2000 , 135, 1285-90		10
9	Parenchymal liver injury in orthotopic liver transplantation. <i>Transplantation</i> , 2000 , 69, 2079-84	1.8	16
8	Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression. <i>FASEB Journal</i> , 1999 , 13, 563-71	0.9	85
7	First experiences with mesh wrapping for parenchymal liver injuries in orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 1999 , 31, 538-9	1.1	1
6	Preservation of the liver: is it possible to extend the time of storage?. <i>Transplantation Proceedings</i> , 1999 , 31, 2074-6	1.1	8
5	It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998 , 50, 37-46	4.4	48
4	Late ureteral obstruction after kidney transplantation. <i>Transplant International</i> , 1997 , 10, 65-68	3	11
3	The impact of liver transplantation on endocrine status in men. <i>Clinical Endocrinology</i> , 1996 , 44, 461-6	3.4	43
2	Immunological risk factors are solely responsible for primary non-function of renal allografts. <i>Transplant International</i> , 1994 , 7 Suppl 1, S294-7	3	
1	Andrological status before and after liver transplantation. <i>Journal of Urology</i> , 1994 , 151, 1251-4	2.5	35

